Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim

    Research output: Contribution to journalArticlepeer-review

    38 Scopus citations

    Fingerprint

    Dive into the research topics of 'Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study'. Together they form a unique fingerprint.

    Medicine & Life Sciences